Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Other

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

By The Northwire Desk — AI Analysis Oct 22, 2025 · 07:30 BCT · 17.77 BRIACELL THERAPEUTICS CORP. J
BCT · Price

Executive Summary

  • Independent Data Safety Monitoring Board (DSMB) issued its fourth consecutive positive recommendation, indicating no safety concerns for BriaCell’s pivotal Phase 3 trial of Bria‑IMT™ plus a checkpoint inhibitor in metastatic breast cancer.
  • The DSMB advised the study continue without any protocol modifications, reinforcing confidence in the regimen’s safety and tolerability profile.
  • The trial is conducted under FDA Fast Track Designation, underscoring its significance for an unmet medical need.

Key Details

  • DSMB Recommendation: Fourth consecutive positive safety recommendation; no safety concerns identified.
  • Study Status: Ongoing Phase 3 pivotal trial (NCT06072612) of Bria‑IMT™ + immune checkpoint inhibitor in metastatic breast cancer patients.
  • Regulatory Context: Trial operates under FDA Fast Track Designation, reflecting high unmet need.
  • Frequency of DSMB Reviews: Quarterly meetings per study protocol.
  • CEO Quote: “Repeated consecutive DSMB positive recommendations further strengthen our confidence in the excellent safety and tolerability profile of the BriaCell regimen.” – Dr. William V. Williams, President & CEO.

Notable Quotes

“We strongly believe in Bria‑IMT’s potential to transform cancer care and remain determined to make it a reality for patients with metastatic breast cancer who face urgent medical needs.” – Dr. William V. Williams, President & CEO.

Read the original news release →

More from BRIACELL THERAPEUTICS CORP. J

Jun 25, 2026 · 07:30

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)

M&A / Property Jun 02, 2026 · 16:05

BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment

Financings Jun 01, 2026 · 07:30

BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

Other May 31, 2026 · 19:59

BriaCell Therapeutics Announces Pricing of Offering

Financings May 31, 2026 · 03:20

Briacell prices shares of $4.7M offering at $3.25 each

Financings May 26, 2026 · 07:30

Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

Other